- Home
- PTA vs PCRX Comparison
PTA vs PCRX Comparison
Compare PTA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- PCRX
- Stock Information
- Founded
- PTA 2020
- PCRX 2006
- Country
- PTA United States
- PCRX United States
- Employees
- PTA N/A
- PCRX N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PTA Finance
- PCRX Health Care
- Exchange
- PTA Nasdaq
- PCRX Nasdaq
- Market Cap
- PTA 1.1B
- PCRX 1.2B
- IPO Year
- PTA N/A
- PCRX 2011
- Fundamental
- Price
- PTA $19.97
- PCRX $21.77
- Analyst Decision
- PTA
- PCRX Buy
- Analyst Count
- PTA 0
- PCRX 8
- Target Price
- PTA N/A
- PCRX $28.38
- AVG Volume (30 Days)
- PTA 159.2K
- PCRX 487.4K
- Earning Date
- PTA 01-01-0001
- PCRX 08-05-2025
- Dividend Yield
- PTA 8.31%
- PCRX N/A
- EPS Growth
- PTA N/A
- PCRX N/A
- EPS
- PTA N/A
- PCRX N/A
- Revenue
- PTA N/A
- PCRX $702,772,000.00
- Revenue This Year
- PTA N/A
- PCRX $7.92
- Revenue Next Year
- PTA N/A
- PCRX $11.02
- P/E Ratio
- PTA N/A
- PCRX N/A
- Revenue Growth
- PTA N/A
- PCRX 3.08
- 52 Week Low
- PTA $15.84
- PCRX $11.16
- 52 Week High
- PTA $19.67
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- PTA 56.22
- PCRX 38.56
- Support Level
- PTA $19.75
- PCRX $21.26
- Resistance Level
- PTA $20.01
- PCRX $22.74
- Average True Range (ATR)
- PTA 0.18
- PCRX 0.84
- MACD
- PTA -0.01
- PCRX -0.00
- Stochastic Oscillator
- PTA 73.47
- PCRX 19.25
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.